OM1's PhenOM ® Foundation AI Surpasses One Billion Years of Health History in Model Training
BOSTON--(BUSINESS WIRE)-- OM1, a leading provider of AI-driven insights for life sciences and healthcare organizations, today announced a major milestone in the development of its groundbreaking PhenOM ® Foundation Model. The model has now been trained on more than one billion years of patient health histories, representing the largest model of its kind to date.
PhenOM is a next-generation AI platform that identifies patient phenotypes and accurately predicts diagnoses, outcomes, and treatment effects at scale. By analyzing structured and unstructured data from diverse healthcare sources, the PhenOM API delivers real-time predictions on thousands of outcomes from hospitalizations to heart attacks and strokes across a wide range of diseases and populations.
'Training AI models on real-world health data at this scale opens up unprecedented opportunities to improve how we predict, diagnose, and treat disease,' said Dr. Richard Gliklich, CEO of OM1. 'PhenOM is not just a model, it's an adaptive foundation layer built on billions of clinical events, enabling intelligent healthcare applications and research across the entire ecosystem.'
In addition to predicting outcomes, the PhenOM model evaluates the safety and benefits of treatments in specific patients and subpopulations. This enables healthcare stakeholders to identify underdiagnosed or undertreated patients, improve clinical trial efficiency, and support precision health initiatives.
OM1's innovation in AI-driven real-world evidence is underpinned by a strong and expanding intellectual property portfolio. Eight U.S. patents have been issued to date for OM1's technologies, with a ninth patent scheduled to issue on May 20, 2025, further strengthening the company's position as a leader in applied clinical AI. OM1 is currently working with a range of partners, including leading healthcare systems, health plans, life sciences organizations, and software companies, to integrate PhenOM into programs that target population health, value-based care, and drug development.
Meet our PhenOM experts and learn more at ISPOR 2025, booth #1500.
About OM1:
OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
35 minutes ago
- Business Wire
KBRA Releases Global ABS 2025: Day 3 Recap
LONDON--(BUSINESS WIRE)--KBRA releases a Day 3 recap of the 29th annual Global ABS conference. The third and final day of the Global ABS 2025 conference focused on private credit and featured a series of engaging roundtable discussions. Highlights included a fireside chat and discussion among several industry legends. Topics covered included net asset value (NAV) lending, asset-based finance (ABF), and broader trends in private credit. Click here to view a recap of some of the day's panel discussions. Recent Publications About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1009820
Yahoo
36 minutes ago
- Yahoo
KBRA Releases Global ABS 2025: Day 3 Recap
LONDON, June 13, 2025--(BUSINESS WIRE)--KBRA releases a Day 3 recap of the 29th annual Global ABS conference. The third and final day of the Global ABS 2025 conference focused on private credit and featured a series of engaging roundtable discussions. Highlights included a fireside chat and discussion among several industry legends. Topics covered included net asset value (NAV) lending, asset-based finance (ABF), and broader trends in private credit. Click here to view a recap of some of the day's panel discussions. Recent Publications Global ABS 2025: Day 1 Recap Global ABS 2025: Day 2 Recap KBRA's European Securitisation Survey: Positive Sentiment Grows European CLOs: Too Big to Hold? European Securitisation: Positive Trend Continues European Auto ABS Indices: April 2024 UK Mortgage and Housing Trends: May 2024 Update Navigating European CLO Tail Risk: Mind the Amortisation Gap European Significant Risk Transfer Symposium 2024 Recap European CLO Manager Style Comparisons: April 2024 Update Private Credit: Potential for European MM and Direct Lending CLOs Irish Mortgage and Housing Trends 2024 European Structured Finance Sector Outlook: Turbulence Ahead About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1009820 View source version on Contacts Gordon Kerr, European Macro Strategist+44 20 8148 Media Contact Adam Tempkin, Director of Communications+1 Business Development Contacts Mauricio Noé, Co-Head of Europe+44 20 8148 Miten Amin, Managing Director+44 20 8148
Business Upturn
an hour ago
- Business Upturn
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
By GlobeNewswire Published on June 13, 2025, 11:30 IST Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025 , on June 16, in Boston, US; , on June 16, in Boston, US; Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group ), on June 18, in Paris, France; (hosted by ), on June 18, in Paris, France; International Neoantigen Summit , on June 24, 2025, in Amsterdam, Netherlands; , on June 24, 2025, in Amsterdam, Netherlands; International Academy of Oral Oncology 2025 (IAOO), on July 18, in Liverpool, UK. Following the positive clinical data on our individualized neoantigen cancer vaccine TG4050, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here), Transgene together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a virtual event available on Transgene website and here. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Additional information about Transgene is available at: Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250613_Transgene_Upcoming_Events_EN Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
